Get App

FDA approves generic Valsartan amid drug shortage

Several drugmakers, including Teva Pharmaceutical Industries Ltd and Mylan NV, have recalled batches of valsartan as the drugs have been found to contain probable carcinogens.
  • Updated On Mar 13, 2019 at 11:25 AM IST
The U.S. Food and Drug Administration on Tuesday approved a new generic of heart medicine Valsartan and said it prioritized the drug's review to help relieve recent shortage as manufacturers around the world have pulled the treatment from market.

Several drugmakers, including Teva Pharmaceutical Industries Ltd and Mylan NV, have recalled batches of Valsartan as the drugs have been found to contain probable carcinogens.

The approval of the generic, Diovan, was granted to Alkem Laboratories Ltd, the FDA said in a statement. (Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

  • Published On Mar 13, 2019 at 08:18 AM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App